<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604797</url>
  </required_header>
  <id_info>
    <org_study_id>SShen</org_study_id>
    <nct_id>NCT02604797</nct_id>
  </id_info>
  <brief_title>Analgesia Effects of Nalbuphine vs Sulfentanil</brief_title>
  <official_title>Analgesia Effects of Nalbuphine vs Sulfentanil in Patient-controlled Intravenous Analgesia After Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cesarean section may result in great trauma and postoperative pain. Besides incision pain,&#xD;
      uterine contraction pain is another source of postoperative pain after cesarean section. In&#xD;
      clinical practice, a large amount of uterine contraction agent is routinely applied after&#xD;
      cesarean section so as to promote involution of uterus and reduce postoperative hemorrhage,&#xD;
      which also causes great uterine contraction pain. Acute pain is the risk factor of chronic&#xD;
      pain, and may postpone the recovery from labour and influence the quality of life of&#xD;
      parturient. Though various analgesia modules have been attempted, more than 20% parturients&#xD;
      still experience severe postoperative pain, and pain management after cesarean section&#xD;
      remains a challenge to anesthesiologists.&#xD;
&#xD;
      This study aim to compare the effects of nalbuphine hydrochloride vs sufentanil citrate on&#xD;
      patient-controlled intravenous analgesia after cesarean section.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cesarean section may result in great trauma and postoperative pain. Besides incision pain,&#xD;
      uterine contraction pain is another source of postoperative pain after cesarean section. In&#xD;
      clinical practice, a large amount of uterine contraction agent is routinely applied after&#xD;
      cesarean section so as to promote involution of uterus and reduce postoperative hemorrhage,&#xD;
      which also causes great uterine contraction pain. Acute pain is the risk factor of chronic&#xD;
      pain, and may postpone the recovery from labour and influence the quality of life of&#xD;
      parturient. Though various analgesia modules have been attempted, more than 20% parturients&#xD;
      still experience severe postoperative pain, and pain management after cesarean section&#xD;
      remains a challenge to anesthesiologists.&#xD;
&#xD;
      Opiate drugs constitute the baseline medication for postoperative analgesia. However, pure μ&#xD;
      opioid receptor agonist like morphine and fentanyl may induce adverse effects such as nausea,&#xD;
      vomiting, dizziness, drowsiness and respiratory depression. Nalbuphine hydrochloride is an&#xD;
      opiate-like substance structure-related oxymorphone, which is a κ receptor agonist/μ receptor&#xD;
      partial antagonistic type analgesia drug. Specific κ receptor agonist and gene knockout&#xD;
      experiment reveals that κ receptor agonist depresses the visceral pain induced by chemical&#xD;
      stimulation, the effect of which outperforms pure μ opioid receptor agonist. Studies have&#xD;
      discovered that some κ receptor agonists can reduce or inhibit the side effects of μ receptor&#xD;
      agonist such as tolerance or dependence. The adverse effects of μ receptor agonist such as&#xD;
      pruritus, nausea, vomiting, delayed gastric emptying are caused by the drug on peripheral&#xD;
      opioid receptor, and can be relieved by opioid receptor agonist. The structure of nalbuphine&#xD;
      hydrochloride is related to naloxone, an opioid receptor antagonist, therefore, the incidence&#xD;
      of adverse effects of nalbuphine hydrochloride is lower than that of μ receptor agonist. In&#xD;
      recent years, nalbuphine hydrochloride has become more and more popular in postoperative&#xD;
      analgesia. There has been reports on intrathecal administration of nalbuphine hydrochloride&#xD;
      for analgesia after cesarean section, while the effect of intravenous administration of&#xD;
      nalbuphine hydrochloride on analgesia after cesarean section remains undetermined. This study&#xD;
      aim to compare the effects of nalbuphine hydrochloride vs sufentanil citrate on&#xD;
      patient-controlled intravenous analgesia after cesarean section.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores of nalbuphine group</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain scores of sufentanil group</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Usage of nalbuphine of nalbuphine group</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of sufentanil of sufentanil group</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>C.Delivery; Surgery (Previous), Gynecological</condition>
  <arm_group>
    <arm_group_label>Nalbuphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nalbuphine group: nalbuphine 100 mg, ramosetron 0.3mg, background dose 1ml/h,patient-controlled analgesia(PCA) 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sufentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sufentanil group: sufentanil 100ug, ramosetron 0.3mg, background dose 1ml/h, PCA 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalbuphine</intervention_name>
    <description>patient-controlled intravenous analgesia</description>
    <arm_group_label>Nalbuphine</arm_group_label>
    <other_name>nalbuphine 100 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>patient-controlled intravenous analgesia</description>
    <arm_group_label>Sufentanil</arm_group_label>
    <other_name>sufentanil 100ug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flurbiprofen axetil</intervention_name>
    <description>patient-controlled intravenous analgesia</description>
    <arm_group_label>Nalbuphine</arm_group_label>
    <arm_group_label>Sufentanil</arm_group_label>
    <other_name>flurbiprofen axetil 50mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramosetron</intervention_name>
    <description>patient-controlled intravenous analgesia</description>
    <arm_group_label>Nalbuphine</arm_group_label>
    <arm_group_label>Sufentanil</arm_group_label>
    <other_name>ramosetron 0.3mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For primipara with selective cesarean section&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe preeclampsia,&#xD;
&#xD;
          -  pregnancy complicated with diabetes mellitus&#xD;
&#xD;
          -  pregnancy complicated with cardiac disease,&#xD;
&#xD;
          -  gestation age&lt;37W&#xD;
&#xD;
          -  recently use of opiate drugs or nonsteroidal antiinflammatory drugs within 48 h before&#xD;
             operation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaoqiang Huang</last_name>
    <role>Study Director</role>
    <affiliation>Department of Anesthesiology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shen Sun</last_name>
    <email>sunshen1980@126.com</email>
  </overall_contact>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>November 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>November 11, 2015</last_update_submitted>
  <last_update_submitted_qc>November 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Sun Shen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flurbiprofen</mesh_term>
    <mesh_term>Flurbiprofen axetil</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Dsuvia</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

